MSAT

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Jeudi, mai 2, 2024
Transfer, Breast cancer, FDA, The Transfer Agreement, Food, BTC, Research, Trastuzumab, MAA, Insurance, Jazz Pharmaceuticals, MSAT, Abstract, IND, ASCO, Disease, CD28, HER2, Tax, ADC, Three Months, Patient, Society, EMA, Bone marrow, BLA, Standard of care, AACR, Autoimmunity, European Medicines Agency, Pharmaceutical industry

In May 2024, our partner Jazz guided that their plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) for zanidatamab in BTC are proceeding.

Key Points: 
  • In May 2024, our partner Jazz guided that their plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) for zanidatamab in BTC are proceeding.
  • Financial Results for the Three Months Ended March 31, 2024
    Revenue was $10.0 million for the three months ended March 31, 2024 compared to $35.6 million for the same period in 2023.
  • Other income, net increased by $1.9 million for the three months ended March 31, 2024 compared to the same period in 2023.
  • Net loss for the three months ended March 31, 2024 was $31.7 million compared to $24.4 million loss for the same period in 2023.

AffyImmune Therapeutics Appoints Matt Britz as Chief Executive Officer and Pete Gelinas as SVP of CMC

Retrieved on: 
Mardi, mars 19, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, CALD, Control, Thyroid cancer, Growth, Bluebird bio, MAA, Drug discovery, Business, MIT, Britz, Patient, SVP, Marketing Authorisation Application, Merck, MSAT, Business development, Acquisition, CMC, Betibeglogene autotemcel, Technology transfer, Senior, MBA, CMCF, Therapy, Takeda, Equinox Group, Dana–Farber Cancer Institute, Multimedia, Chemical engineering, DFCI, Partnership, Biology, BLA, Pharmaceutical industry

AffyImmune Therapeutics, Inc ., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today the appointment of Matt Britz to Chief Executive Officer and Pete Gelinas as Senior Vice President of Chemistry, Manufacturing, and Controls.

Key Points: 
  • AffyImmune Therapeutics, Inc ., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today the appointment of Matt Britz to Chief Executive Officer and Pete Gelinas as Senior Vice President of Chemistry, Manufacturing, and Controls.
  • Matt is well-suited to lead AffyImmune as CEO as the Company accelerates clinical development of AIC100 in thyroid cancer, and in other indications with high unmet medical need.
  • Matt Britz joined AffyImmune in June 2021 as Senior Vice President (SVP), Business Development and was promoted to Chief Operating Officer in January 2022.
  • Pete Gelinas brings over 15 years of extensive experience in Manufacturing and CMC Product Development to AffyImmune.

Japanese Multinational Biopharmaceutical Company Selects ValGenesis iRisk for Implementing ICH Q14 Framework

Retrieved on: 
Mardi, mars 12, 2024
Quality by design, Patient, MSAT, Software, Process analytical technology, PAT, Safety, ICH

SANTA CLARA, Calif., March 12, 2024 /PRNewswire/ -- ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a Japanese multinational biopharmaceutical company selected ValGenesis iRisk for implementing the ICH Q14 framework on Process Analytical Technology (PAT) analytical methods across its global manufacturing sites.

Key Points: 
  • SANTA CLARA, Calif., March 12, 2024 /PRNewswire/ -- ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a Japanese multinational biopharmaceutical company selected ValGenesis iRisk for implementing the ICH Q14 framework on Process Analytical Technology (PAT) analytical methods across its global manufacturing sites.
  • Already aware of ValGenesis' experience helping customers implement PAT tools, the company approached ValGenesis with a requirement to implement a structured framework covering the ICH Q14 guideline on Analytical Method Development, specifically for PAT.
  • ValGenesis Consulting will lead the implementation of the ICH Q14 framework via a thorough assessment of the customer's current analytical method development practices across its sites, propose a framework for ICH Q14 adoption using ValGenesis iRisk , build the case for the customer's product in ValGenesis iRisk, and train a group of key users within their global MSAT team on the utilization of the framework on ValGenesis iRisk with sandbox access.
  • With ValGenesis iRisk, our customer is assured of a risk-based Quality by Design (QbD) approach to highly compliant and cost-effective manufacturing."

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Mercredi, mars 6, 2024
Senior, Research, Fulvestrant, Sale, University, NBI, Tax, MSAT, Plasma, CD28, BTC, NASDAQ Biotechnology Index, Pain, Rat, BLA, Standard of care, Antibody, HER2, MD Anderson Cancer Center, Abstract (summary), GAAP, Therapy, Carcinoma, Abstract, Depreciation, Partnership, Camptothecin, Manuscript, Conference, Partner, IND, NMPA, Jazz Pharmaceuticals, PFS, BeiGene, FDA, Spacecraft, Pembrolizumab, CDX, ADC, OS, Society, Patient, Pharmaceutical industry

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.

Sasken Powers World's First High-Speed Satellite Broadband Device for Critical Communications

Retrieved on: 
Jeudi, janvier 18, 2024
3GPP, Tsunami, GEO, Sasken Technologies, Communication, Software, NW, LTE, SATCOM, Human, MSAT, Engineering, Calamity, Mobile phone

As pioneers in the SatCom industry, Sasken has designed, developed, and deployed the MSE hardware and software, revolutionizing the satellite communication industry.

Key Points: 
  • As pioneers in the SatCom industry, Sasken has designed, developed, and deployed the MSE hardware and software, revolutionizing the satellite communication industry.
  • The introduction of LTE over mobile satellite equipment brings standard 3GPP services over the satellite infrastructure, transforming the legacy satellite network infrastructure into a standard and interoperable telecom network.
  • "Sasken continues to break barriers and redefine the boundaries of technological innovation," said Mr. Rajiv C. Mody, Chairman & Managing Director, Sasken Technologies.
  • For more information about the MSE LTE technology-based satellite product and Sasken, please visit our website www.sasken.com

Sasken Powers World's First High-Speed Satellite Broadband Device for Critical Communications

Retrieved on: 
Jeudi, janvier 18, 2024
3GPP, Tsunami, GEO, Sasken Technologies, Communication, Software, NW, LTE, SATCOM, Human, MSAT, Engineering, Calamity, Mobile phone

As pioneers in the SatCom industry, Sasken has designed, developed, and deployed the MSE hardware and software, revolutionizing the satellite communication industry.

Key Points: 
  • As pioneers in the SatCom industry, Sasken has designed, developed, and deployed the MSE hardware and software, revolutionizing the satellite communication industry.
  • The introduction of LTE over mobile satellite equipment brings standard 3GPP services over the satellite infrastructure, transforming the legacy satellite network infrastructure into a standard and interoperable telecom network.
  • "Sasken continues to break barriers and redefine the boundaries of technological innovation," said Mr. Rajiv C. Mody, Chairman & Managing Director, Sasken Technologies.
  • For more information about the MSE LTE technology-based satellite product and Sasken, please visit our website www.sasken.com

Flash News: OKX Wallet Now Integrated with MultiSat, a Community-Owned Multichain Inscription Marketplace

Retrieved on: 
Mardi, janvier 16, 2024
Web3, Community, MSAT, OKX, Cryptocurrency

SINGAPORE, Jan. 16, 2024 (GLOBE NEWSWIRE) -- OKX , a leading Web3 technology company, has issued updates for January 16, 2024.

Key Points: 
  • SINGAPORE, Jan. 16, 2024 (GLOBE NEWSWIRE) -- OKX , a leading Web3 technology company, has issued updates for January 16, 2024.
  • OKX Wallet Now Integrated with MultiSat, a Community-Owned Multichain Inscription Marketplace
    OKX Wallet is now integrated with MultiSat , a community-owned multichain inscription marketplace.
  • This integration enables OKX Wallet users to seamlessly engage with MultiSat's range of solutions, including inscribing, trading and earning, via web extension.
  • To access MultiSat, OKX Wallet users simply need to:

Applied StemCell, Inc. Strengthens Executive Leadership with Two Key Appointments

Retrieved on: 
Lundi, décembre 4, 2023
Construction & Property, Genetics, REIT, Health Technology, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, B cell, Sigma-Aldrich, Acquisition, Research, GMP, Molecular biology, Duke University, Commercial, CDMO, MSAT, ASC, Doctor of Philosophy, Marketing, Boston University, Advanced Therapy Medicinal Product, MBA, University, Champaign–Urbana metropolitan area, CCO, Dendreon, ATMP, Fine chemical, Management, Science, Biology

The recent acquisition of the company by QHP Capital in October has set the stage for an ambitious expansion focused on supporting cell manufacturing from development through commercialization.

Key Points: 
  • The recent acquisition of the company by QHP Capital in October has set the stage for an ambitious expansion focused on supporting cell manufacturing from development through commercialization.
  • George Hong joins Applied StemCell, Inc. as Chief Commercial Officer (CCO), bringing more than 20 years of experience in academic and industry roles within life sciences, serving as a sales, marketing, and commercial executive with increasing responsibilities.
  • Prior to joining Applied StemCell, Tim held key positions, including VP of Commercial Manufacturing at Adrian Biotech, VP of Manufacturing Science and Technology (MSAT) at RoslinCT, and over 8 years in commercial manufacturing and quality positions at Dendreon.
  • "We are thrilled to have George and Tim as valuable additions to the ASC leadership team," expressed Dr. Ruby Chen-Tsai, CEO of Applied StemCell.

Universal Technical Institute to Consolidate Houston Operations to Better Serve Students

Retrieved on: 
Mardi, décembre 5, 2023
Aviation, BMW, Ford, Robotics, MSAT, Student, Faculty, UTI, College of Engineering (KNUST), Automation, Curriculum, HVACR, Service King Collision Repair, Universal Technical Institute, Transport, Nursing

PHOENIX, Dec. 5, 2023 /PRNewswire/ -- Universal Technical Institute (UTI), the transportation, skilled trades, and energy education division of Universal Technical Institute, Inc., today announced it will consolidate its Houston operations to align the curriculum, student facing systems, and support services to better serve students seeking careers in in-demand fields.  As part of the transition, the MIAT-Houston campus, acquired in November 2021, will begin operating under the UTI brand and implement a phased teach-out agreement starting in May 2024. MIAT-Houston and UTI-Houston are strategically located less than a quarter of a mile apart off interstate 45 in the north section of the city.  Both facilities will remain in use post-consolidation.

Key Points: 
  • PHOENIX, Dec. 5, 2023 /PRNewswire/ -- Universal Technical Institute (UTI) , the transportation, skilled trades, and energy education division of Universal Technical Institute, Inc. , today announced it will consolidate its Houston operations to align the curriculum, student facing systems, and support services to better serve students seeking careers in in-demand fields.
  • MIAT-Houston and UTI-Houston are strategically located less than a quarter of a mile apart off interstate 45 in the north section of the city.
  • Other benefits include allowing future students to complete certain programs more quickly," said Tracy Lorenz, President of the UTI Division.
  • Lorenz further commented, "We are taking all possible steps to make this a seamless and positive experience for our students.

Valitor Expands Leadership Team with Appointment of Omkar Joshi, Ph.D. as Vice President of CMC

Retrieved on: 
Mercredi, juillet 19, 2023
Doctor of Philosophy, Oregon State University, AMD, Biotechnology, CMC, National Center for Manufacturing Sciences, Control, Bayer, Patient, Chemistry, Ophthalmology, MSAT, Growth, Spacecraft, Therapy, Chemical engineering, A-DNA, Pharmaceutical industry, Fine chemical, Valitor

BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced the appointment of Omkar Joshi, Ph.D., as vice president of CMC (Chemistry, Manufacturing and Controls).

Key Points: 
  • BERKELEY, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced the appointment of Omkar Joshi, Ph.D., as vice president of CMC (Chemistry, Manufacturing and Controls).
  • “We are delighted to welcome Omkar to Valitor as he brings deep knowledge and a wealth of experience that will be instrumental in the next phase of our growth,” said Steven Lo, chief executive officer of Valitor.
  • “Beyond his proven technical capabilities, impressive tenure as an experienced technical operations leader and successful CMC track record, Omkar has also proven his adeptness at building and leading high-performing teams in both small startup companies and big pharma.
  • Dr. Joshi has extensive experience working across various modalities including recombinant proteins, monoclonal antibodies, ADCs, cell therapies and gene therapies.